Lamellar Ichthyosis Market Dynamics Indicate Upward Trajectory Through 2032, Reports DelveInsight

DelveInsight's "Lamellar Ichthyosis Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Lamellar Ichthyosis, historical and forecasted epidemiology as well as the Lamellar Ichthyosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Lamellar Ichthyosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Lamellar Ichthyosis Market Forecast
https://www.delveinsight.com/sample-request/lamellar-ichthyosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Lamellar Ichthyosis Market Report:
• The Lamellar Ichthyosis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In March 2024, Timber Pharmaceuticals, Inc., a subsidiary of LEO Pharma, presented preliminary findings from the ASCEND trial during a late-breaking session at the 2024 American Academy of Dermatology (AAD) Annual Meeting. The ASCEND trial evaluates TMB-001, an investigational polyethylene glycol (iPEGTM)-based topical isotretinoin, being developed to treat moderate-to-severe X-linked and autosomal recessive congenital ichthyosis (CI). CI is a group of rare genetic keratinization disorders characterized by dry, thickened, and scaling skin. Currently, no FDA-approved treatments are available specifically for CI.
• Lamellar ichthyosis (LI), a rare hereditary skin condition that manifests from birth, is described by NORD (2022). It belongs to a group of three hereditary skin conditions known as ARCI (autosomal recessive congenital ichthyoses)
• According to the Foundation For Ichthyosis and Related Skin Types, lamellar ichthyosis affects both men and women equally and is thought to affect 1 in 300,000 live births in the US
• In the US, lamellar ichthyosis affects roughly 1 in 200,000 people. 1 in 200,000-300,000 reports of predominance are the most common. In around 8% of cases, the parents are consanguineous
• Key Lamellar Ichthyosis Companies: Timber Pharmaceuticals, Krystal Biotech, GSK, Timber Pharmcecuticals, Janssen Scientific, Patagonia Pharma, Timber Pharmcuticals, Crown Laboratories, Inc, and others
• Key Lamellar Ichthyosis Therapies: TMB-001, KB105, Liarozole, TMB-001, Ustekinumab, PAT-001, Isotretinoin, 146-9251, and others
• The Lamellar Ichthyosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Lamellar Ichthyosis pipeline products will significantly revolutionize the Lamellar Ichthyosis market dynamics.

Lamellar Ichthyosis Overview
Skin cells are created properly, but in Lamellar Ichthyosis (LI), a rare genetic condition, they do not split normally at the surface of the outermost layer of skin and are not removed as soon as they should be, which results in the creation of scale.

Get a Free sample for the Lamellar Ichthyosis Market Report
https://www.delveinsight.com/report-store/lamellar-ichthyosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Lamellar Ichthyosis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Lamellar Ichthyosis Epidemiology Segmentation:
The Lamellar Ichthyosis market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Lamellar Ichthyosis
• Prevalent Cases of Lamellar Ichthyosis by severity
• Gender-specific Prevalence of Lamellar Ichthyosis
• Diagnosed Cases of Episodic and Chronic Lamellar Ichthyosis

Download the report to understand which factors are driving Lamellar Ichthyosis epidemiology trends @ Lamellar Ichthyosis Epidemiology Forecast
https://www.delveinsight.com/sample-request/lamellar-ichthyosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Lamellar Ichthyosis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Lamellar Ichthyosis market or expected to get launched during the study period. The analysis covers Lamellar Ichthyosis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Lamellar Ichthyosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Lamellar Ichthyosis Therapies and Key Companies
• TMB-001: Timber Pharmaceuticals
• KB105: Krystal Biotech
• Liarozole: GSK
• TMB-001: Timber Pharmcecuticals
• Ustekinumab: Janssen Scientific
• PAT-001: Patagonia Pharma
• Isotretinoin: Timber Pharmcuticals
• 146-9251: Crown Laboratories, Inc

Discover more about therapies set to grab major Lamellar Ichthyosis market share @ Lamellar Ichthyosis Treatment Market
https://www.delveinsight.com/sample-request/lamellar-ichthyosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Lamellar Ichthyosis Market Strengths
• Ongoing Search for Cure - Along with clinical trials in Lamellar Ichthyosis, various institute/ organization/ and groups are conducting research to find cure for this disease.
• Various Organization and Foundation Support - Organizations and government level support has aided in further development of angleman syndrome treatment

Lamellar Ichthyosis Market Opportunities
• Lack of treatment protocols
• Research funding
• Biomarker research
• Integrative and novel therapies

Scope of the Lamellar Ichthyosis Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Lamellar Ichthyosis Companies: Timber Pharmaceuticals, Krystal Biotech, GSK, Timber Pharmcecuticals, Janssen Scientific, Patagonia Pharma, Timber Pharmcuticals, Crown Laboratories, Inc, and others
• Key Lamellar Ichthyosis Therapies: TMB-001, KB105, Liarozole, TMB-001, Ustekinumab, PAT-001, Isotretinoin, 146-9251, and others
• Lamellar Ichthyosis Therapeutic Assessment: Lamellar Ichthyosis current marketed and Lamellar Ichthyosis emerging therapies
• Lamellar Ichthyosis Market Dynamics: Lamellar Ichthyosis market drivers and Lamellar Ichthyosis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Lamellar Ichthyosis Unmet Needs, KOL's views, Analyst's views, Lamellar Ichthyosis Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.